Taking into account the aforementioned existing evidence regarding TP53 genomic vulnerability, coupled with the newly reported, significant TD expression patterns in RCCs, we speculate that it is highly likely for CPD-induced TP53 mutations to be involved in RCC carcinogenesis, or at least in RCC tumor progression. The gene discussed is TP53; the disease is neoplasm.